Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial
Title:
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial
Author:
Velikova, Galina Morden, James P Haviland, Joanne S Emery, Charlotte Barrett-Lee, Peter Earl, Helena Bloomfield, David Brunt, Adrian Murray Canney, Peter Coleman, Robert Verrill, Mark Wardley, Andrew Bertelli, Gianfilippo Ellis, Paul Stein, Rob Bliss, Judith M Cameron, David
Appeared in:
Lancet oncology
Paging:
Volume 24 () nr. 12 pages 1359-1374
Year:
2023
Contents:
Publisher:
The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license